RXi Pharmaceuticals Corporation - Product Pipeline Review - 2016

  • ID: 3804664
  • Company Profile
  • 55 pages
  • Global Markets Direct
1 of 4
RXi Pharmaceuticals Corporation - Product Pipeline Review - 2016

Summary

‘RXi Pharmaceuticals Corporation - Product Pipeline Review - 2016’, provides an overview of the RXi Pharmaceuticals Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by RXi Pharmaceuticals Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of RXi Pharmaceuticals Corporation
- The report provides overview of RXi Pharmaceuticals Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses RXi Pharmaceuticals Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features RXi Pharmaceuticals Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate RXi Pharmaceuticals Corporation’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for RXi Pharmaceuticals Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RXi Pharmaceuticals Corporation’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

RXi Pharmaceuticals Corporation Snapshot

RXi Pharmaceuticals Corporation Overview

Key Information

Key Facts

RXi Pharmaceuticals Corporation - Research and Development Overview

Key Therapeutic Areas

RXi Pharmaceuticals Corporation - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

RXi Pharmaceuticals Corporation - Pipeline Products Glance

RXi Pharmaceuticals Corporation - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

RXi Pharmaceuticals Corporation - Early Stage Pipeline Products

IND/CTA Filed Products/Combination Treatment Modalities

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

RXi Pharmaceuticals Corporation - Drug Profiles

diphencyprone

Product Description

Mechanism of Action

R&D Progress

RXI-109

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotide to Inhibit CTGF for PVR

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotide Inhibiting MDM2 for Retinoblastoma

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotide to Inhibit SOD-1 for ALS

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotide to Inhibit VEGF for Macular Degeneration

Product Description

Mechanism of Action

R&D Progress

RXI-209

Product Description

Mechanism of Action

R&D Progress

bevasiranib sodium

Product Description

Mechanism of Action

R&D Progress

MMP-26051

Product Description

Mechanism of Action

R&D Progress

MMP-26052

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotide to Inhibit Angiopoietin-2 for Retinal Disease and Cancer

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotide to Inhibit HIF-1 Alpha for Retinal Disease and Cancer

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotide to Inhibit ICAM-1 for Retinal Diseases and Cancer

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotides to Inhibit Complement C3 for Ophthalmology

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotides to Inhibit TNF-alpha for Autoimmune Disorders

Product Description

Mechanism of Action

R&D Progress

TRY-26071

Product Description

Mechanism of Action

R&D Progress

TRY-26077

Product Description

Mechanism of Action

R&D Progress

RXi Pharmaceuticals Corporation - Pipeline Analysis

RXi Pharmaceuticals Corporation - Pipeline Products by Target

RXi Pharmaceuticals Corporation - Pipeline Products by Route of Administration

RXi Pharmaceuticals Corporation - Pipeline Products by Molecule Type

RXi Pharmaceuticals Corporation - Pipeline Products by Mechanism of Action

RXi Pharmaceuticals Corporation - Recent Pipeline Updates

RXi Pharmaceuticals Corporation - Dormant Projects

RXi Pharmaceuticals Corporation - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

bevasiranib sodium

RXi Pharmaceuticals Corporation - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 55List of Tables

RXi Pharmaceuticals Corporation, Key Information

RXi Pharmaceuticals Corporation, Key Facts

RXi Pharmaceuticals Corporation - Pipeline by Indication, 2016

RXi Pharmaceuticals Corporation - Pipeline by Stage of Development, 2016

RXi Pharmaceuticals Corporation - Monotherapy Products in Pipeline, 2016

RXi Pharmaceuticals Corporation - Phase II, 2016

RXi Pharmaceuticals Corporation - Phase I, 2016

RXi Pharmaceuticals Corporation - IND/CTA Filed, 2016

RXi Pharmaceuticals Corporation - Preclinical, 2016

RXi Pharmaceuticals Corporation - Discovery, 2016

RXi Pharmaceuticals Corporation - Pipeline by Target, 2016

RXi Pharmaceuticals Corporation - Pipeline by Route of Administration, 2016

RXi Pharmaceuticals Corporation - Pipeline by Molecule Type, 2016

RXi Pharmaceuticals Corporation - Pipeline Products by Mechanism of Action, 2016

RXi Pharmaceuticals Corporation - Recent Pipeline Updates, 2016

RXi Pharmaceuticals Corporation - Dormant Developmental Projects,2016

RXi Pharmaceuticals Corporation - Discontinued Pipeline Products, 2016 52List of Figures

RXi Pharmaceuticals Corporation - Pipeline by Top 10 Indication, 2016

RXi Pharmaceuticals Corporation - Pipeline by Stage of Development, 2016

RXi Pharmaceuticals Corporation - Monotherapy Products in Pipeline, 2016

RXi Pharmaceuticals Corporation - Pipeline by Top 10 Target, 2016

RXi Pharmaceuticals Corporation - Pipeline by Route of Administration, 2016

RXi Pharmaceuticals Corporation - Pipeline by Molecule Type, 2016

RXi Pharmaceuticals Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll